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Microcomputed Tomography Technique
for In Vivo Three-Dimensional Fat Tissue
Volume Evaluation After Polymer Injection
Sarah Berndt, PhD,1 Ioana Konz, PhD,2 Didier Colin, PhD,3 Ste´phane Germain,3 Brigitte Pittet-Cue´nod, MD,1
Harm-Anton Klok, PhD,2 and Ali Modarressi, MD, PD1
Tissue engineering technologies are new and promising techniques in fat tissue reconstruction. However, to
assess their efficacy before any clinical application, in vivo experiments are mandatory. This study assesses
whether microcomputed tomography (CT) scan imaging is suitable to analyze in vivo the behavior of injected
engineered polymer and changes in fat tissue. The volume of mice inguinal fat pads and the resorption rate of
different polymers were analyzed by CT scan for up to 3 months. Different biomaterials were used, includ-
ing our innovative microspheres loaded with oleic acid. We were able to follow in vivo the polymer and the
fat volume of the same animals during a long-term follow-up of 90 days. Semiautomatic three-dimensional
quantification allowed to determine the fat volume enhancement after injection, as well as the resorption rate of
our product compared to other biomaterials (i.e., polylactic and hyaluronic acid) until 90 days. Our results
demonstrate the encouraging proof-of-principle evidence for the application of micro-CT scan technology to
follow in vivo biodegradable polymers in a fat tissue engineering approach. This noninvasive technique offers
the advantages of the long-term follow-up of fat tissue and synthetic materials in the same animals, which
allows both a scientific evaluation of the measurements and the reduction of the number of animals used in
in vivo protocols in accordance with the 3 ‘‘R’’ principles governing the use of animals in science.
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Introduction
Soft tissue reconstruction following trauma or cancertreatment or for aesthetic indications is challenging. Au-
tologous fat grafting is now considered as the gold standard
technique to augment or fill soft-tissue defects.1 However,
this surgical approach may not be feasible in the absence
of donor sites in thin patients. Moreover, as part of the grafted
fat is resorbed and large fat volume cannot be transferred
at each surgical procedure, several interventions are required.
Therefore, adipose tissue engineering may provide a good
alternative. Currently, new clinical solutions are under de-
velopment using bioactive products that can generate adi-
pose tissue.2 In some settings, poly(lactic-co-glycolic acid)
(PLGA) is used as a scaffold for seeding cells in vitro and
then reimplanted for a longer term to engineer adipose tissue
in vivo.3,4 To assess the amount and the quality of adipose
tissue formed, we performed a histomorphometric analysis
on all tissue sections. However, this experimental process is
time consuming and not suitable for the examination of large
volumes of fat. In addition, it leads to the sacrifice of many
animals to obtain data from sequential measurements. In this
study, we used PLGA as a vehicle to deliver fat component
(oleic acid [OA]) in situ to the target tissue with the aim to
evaluate the accuracy of a three-dimensional (3D) micro-
computed tomography (CT) scan to follow in vivo biomate-
rials and fat volume changes. The advantages are the long-term
follow-up of fat volume in the same animals, which allows
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both to analyze the scientific values of the measurements
and to reduce the number of animals used in in vivo pro-
tocols according to the 3 ‘‘R’’ regulations governing animal
ethics. To validate our technique, our PLGA was loaded
with OA, as well as other different commercial soft tissue
fillers, to assess the behavior of our new biomaterial to in-
crease adipose tissue in situ by the injection of biodegrad-
able microspheres loaded with lipids.
Materials and Methods
Biodegradable microspheres loaded with lipids
We developed a resorbable synthetic PLGA microsphere
loaded with OA. When injected, these microspheres deliver
free fatty acids to the adipocytes in situ, thus allowing local
fat tissue augmentation. Blank PLGA microspheres were
prepared by the single emulsion (O/W)-solvent evapora-
tion method as described elsewhere.5 The OA-loaded PLGA
microspheres were prepared by mixing OA with the PLGA-
containing dichloromethane phase (O). The size, surface as-
pect, and the content of the microspheres were characterized.
The morphological examination of blank and OA-loaded
microspheres was performed using a MERLIN (Carl Zeiss,
Germany) scanning electron microscope as already de-
scribed.6 Particle size is one of the most influential charac-
teristics of the microspheres. Size distribution was measured
by laser diffraction using Mastersizer S (Malvern Instruments
Ltd., United Kingdom). To inject the smallest amount of
microspheres with maximum efficacy, it is crucial to obtain
the highest concentration of OA loaded on microspheres.
Thus, the OA mass was increased from 1%, 2%, and 3% to
7% to obtain microspheres with the highest loading efficiency
(LE) and encapsulation efficiency (EE); quantitative charac-
terization of the OA loading of the microspheres was obtained
using nuclear magnetic resonance (NMR) spectroscopy.
Animal experiments
The concept of the innovation was to increase in situ fat
tissue by the transfer of OA molecules from PLGA micro-
spheres to the adipocytes located in the injection site. To
assess the efficacy and safety of the OA-loaded microspheres,
the volume of the inguinal fat pad of mice injected with OA
was analyzed and compared to control groups. Fat volume
changes and microsphere resorption were measured using a
3D micro-CT.
Animals. In this study, 72 12-week-old BALB C/J female
wild-type mice (Janvier Labs, France) were used. They were
kept under normal maintenance in a clean facility at the Uni-
versity of Geneva Animal Facility. All procedures regarding
animal maintenance and experimental use were conducted
following local regulations and ethics committee approval
(GE49/15). Mice were anesthetized with 2% isoflurane during
the surgical procedure and micro-CT assessment.
In vivo injection of microspheres containing OA compared
to microsphere and control fillers. The behavior of micro-
spheres containing OA was compared to an ‘‘injection solu-
tion’’ (0.5% NaCl with 1% Tween 80) as a control, empty
microspheres, hyaluronic acid (Juvederm ULTRA 4, Al-
lergan, Ireland), and poly-L-lactic acid (PLA) (Sculptra;
Sinclair Pharma, France). At present, the two latter products
are considered to be the state-of-the-art fillers on the market.
Juvederm ULTRA 4 is a highly cross-linked hyaluronic acid,
which is resorbed after 3–6 months. Sculptra is a PLA, a
biopolymer comparable to PLGA and resorbed after 6–12
months. However, it can offer long-term results due to col-
lagen production provoked by inflammatory reactions.
To obtain a homogenous injectable product, the powder
obtained following the technique described above was re-
suspended in the ‘‘injection solution’’ and filtered using 70mm
Corning cell strainer (Falcon) to obtain a final concentration
of 135mg of OA/mL. According to the manufacturers’ in-
structions for clinical use, Sculptra was suspended at a con-
centration of 16.6mg/mL, and the Juvederm ULTRA 4 was
used without resuspension (Table 1). All products were injected
through a 24G sharp needle connected to a 1mL Luer Lock
syringe and Lipopen (Juva+, Switzerland). Lipopen is an
innovative motorized cordless device that permits the homog-
enous injection of precise amount of a product contained in a
syringe plugged into it. Apart from Juvederm ULTRA 4, the
total volume of each injected product was 100mL per inguinal
fat pad. As Juvederm ULTRA 4 was not diluted, the injected
volume was 40mL. To track the fat volume and polymer re-
sorption over time, the 72 BALB C/J mice (12 weeks old;
weight: 18–23 g) were randomly assigned to six different
experimental conditions (12 animals per group), that is,
naive, saline, empty microspheres, OA-loaded microspheres,
Juvederm, and Sculptra. The left inguinal fat pad (LIFP) was
used as the ‘‘treatment’’ side and the right inguinal fat pad
(RIFP) as an internal control where no injection was performed.
Table 1. In Vivo Experimental Conditions
Experimental
conditions
No. of
mice
Nature of
product
Quantity of product
injected in (100 lL)
Injection
system
Naı¨ve 12 — — —
Saline solution 12 +0.1% Tween — 24G needles
Empty MS 12 PLGA 1%
Mannitol 0.5%
CMC
36.5mg MS 24G needles
Microspheres+OA 12 PLGA+OA
1% mannitol
0.5% CMC
50mg (13.5mg OA +36.5mg MS) 24G needles
Sculptra 12 Polylactic acid 1.66mg 24G needles
Juvederm 12 Hyaluronic acid 40 mL (6mg) 24G needles
CMC, carboxymethylcellulose; MS, microspheres; OA, oleic acid; PLGA, poly(lactic-co-glycolic acid).
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CT scan acquisition and quantification. Mice were an-
esthetized with 2% isoflurane and then subjected to CT
scans in a Triumph micro-positron emission tomography
(PET)/single photon emission computed tomography
(SPECT)/CT system (TriFoil). Abdominal scans were ob-
tained by placing the animal comfortably on its back in the
animal holder and aligning its longitudinal axis parallel to
the image plane. The upper limit area of scanning was set at
the second lumbar vertebra using a two-dimensional (2D)
prescan image. Scans were then obtained at 80 peak kilo-
voltage (kVp) and 160 mA, and 1024 projections were ac-
quired during a 360 rotation with a field view of 71.3mm
(1.7 ·magnification). CT scan analysis was performed at
day 0 before injection and then at day 15, 30, 60, and 90.
The Triumph XO software was used to reconstruct the CT
scans with a matrix of 512 and a voxel size of 0.105mm. CT
scans were then exported as Digital Imaging and Commu-
nications in Medicine (DICOM) files through the software
Amira (FEI). The software OsiriX (Pixmeo) was used to
quantitatively analyze the datasets and generate images.
Regions of interest (ROI) were drawn on contiguous slices
on CT-scans and computed as 3D volumes for the mea-
surement of volumes and densities of the indicated adipose
tissues. The contrast difference was used to discriminate
the fat tissue versus the injected products (saline solution,
empty microspheres, or OA-loaded microspheres).
ROI in the inguinal fat pad areas were delineated on 52
images (1 image of every 10, evenly spaced across the whole
animal depth) on 2D sections on both sides. The upper and
lower limits were set at similar levels of depths between
the animals. The algorithm used by the software then au-
tomatically reconstructed the 3D structure and gave precise
quantification of the volume. CT recognizes different tis-
sues upon their attenuation for X-rays in correlation to their
densities, which are expressed in Hounsfield units (HU). In
our study, muscle attenuation coefficients were set to 0 to
allow direct comparison with fat and polymer attenuation
coefficients.
Statistical analysis
One-way analysis of variance (ANOVA) was used for
multiple comparisons in experiments with one independent
variable. Results are expressed as mean – standard error of
the mean (SEM). Dunnett’s test was used for post hoc
analysis of the significant ANOVA. A difference in mean
values between groups was considered to be significant
when p < 0.05.
Results
Microsphere properties and characterization
The morphological examination demonstrated that blank
PLGA microspheres were spherical and had a smooth sur-
face without pores or cavities. The OA-loaded microspheres
showed a spherical shape with a golf ball-like dimpled
surface (Fig. 1). The size distribution of the blank and OA-
loaded microspheres presented a Gaussian distribution. The
mean volume diameter was 39mm for blank microspheres
and 41 mm for OA-loaded microspheres with a span value of
4.2 and 1, respectively.
The LE increased linearly for the formulation of 1–3%
and formed a plateau with 7% OA loading (Fig. 2). The
handling of particles obtained with a 7% formulation was
difficult, and a change in the morphology of the microspheres
was visible macroscopically. The change in particle charac-
teristics of microspheres obtained with the 7% formulation
was also confirmed by laser diffraction analysis. As shown in
Table 2, when the drug mass was raised from 1% to 3%, the
LE increased at the same rate with a quantitative EE. At a
certain ratio of OA to PLGA, the LE reaches a plateau. When
further increasing the drug mass to 6.7%, the PLGA micro-
spheres could no longer encapsulate the OA acid efficiently
and the EE decreased to almost 50%. Based on these results,
a 3% formulation with 75–80% LE and 100% EE was chosen
for all further experiments.
FIG. 1. Scanning electron
microscopic images of blank
(a) and oleic-acid-loaded (b)
poly(lactic-co-glycolic acid)
microspheres prepared by
single emulsion (O/W)-
solvent evaporation method.
FIG. 2. Graphical representation of the obtained LE versus
theoretical LE using formulations 1–4. LE, loading efficiency.
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Animal experiments: in vivo micro-CT scan
assessment and ex vivo histological analysis
The subcutaneous inguinal fat pad and the injected ma-
terial were easily distinguishable from the surrounding tis-
sues by different tissue density images detected on the CT
scan (Fig. 3). Fat tissues ranged between -125 and -150 HU
in our measurements, while polymers ranged between -25
and -39 HU. This attenuation coefficient differences allowed
to precisely depict small amounts of polymer entrapped
within the fat. In Figure 4, we show how we delineated the
ROI on the control RIFP and on the LIFP to be injected on
the 512 2D images (Fig. 4a) and how the software directly
reconstructed the entire fat pad in 3D (Fig. 4b). After empty
microsphere or OA-loaded microsphere injection, the micro-
CT scan allowed to detect the presence of the product within
the fat tissue. As shown in Figure 5, PLGA has a radiopacity
quite similar to muscle, while fat is a soft tissue and presents
lower values of HU (Fig. 5).
Inguinal fat pad quantification. The noninjected contra-
lateral control RIFP showed a tendency to increase over time,
which could be attributed to normal weight gain increase (less
than 10% increase between the different time points in all the
experimental groups) (Fig. 6).
Injected fat pads showed increased volumes in all groups.
Naive fat pads and those with the ‘‘injection solution’’ as the
control and Sculptra had the same tendency as the RIFP, that
is, a continuous fat pad volume increase of up to 10% at day
90. Fat pads injected with the empty microspheres peaked
at day 15 with a 76% volume increase and then showed a
reduction at day 90 with 68% of fat pad increase. In the OA-
loaded microsphere group, the volume increase peaked
at day 30 (87%) and then reduced to 45% at day 90. In the
Juvederm group, the volume increased at day 15 and re-
mained stable until day 90 with an 81% volume increase
(Fig. 7).
Injected product resorption results. To assess the product
resorption, the volume of the injected material over time was
plotted (Fig. 8). The synthetic material was only detectable in
the empty microsphere, OA-loaded microsphere, and Juve-
derm ULTRA 4 groups. Resorption was almost complete
after 3 months for the empty microsphere and OA-loaded
microsphere groups. In the empty microsphere group, we
observed 18% volume resorption after 30 days, 64% after
60 days, and 75% after 90 days. In the OA-loaded micro-
sphere group, the resorption rate was 25% after 30 days, 70%
after 60 days, and 93% after 90 days.
In comparison, the highly cross-linked hyaluronic acid
(Juvederm) remained more stable over time: 10% resorption
after 30 days, 54%after 60 days, and 56%after 90 days. Sculptra
did not show any obvious polymer residue in the fat pad.
Discussion
In situ adipose tissue engineering is of prime importance
because of the increasing need for soft tissue filler proce-
dures.7 Currently, most adipose tissue engineering ap-
proaches imply the use of living cells and/or biomolecules
and/or biocompatible scaffolds.8 Before any clinical use of
these approaches, the assessment of these components after
in vivo implantation is mandatory. To our knowledge, little
has been reported on the in vivo follow-up of these tech-
niques in animal models.
Three-dimensional micro-CT has already been used by
Phipps et al. to follow the evolution of fat graft implanted
without any biomaterial under the scalp of mice.9 Previous
studies have also shown high correlations between micro-
CT-derived fat pad volumes and their weight after exci-
sion,10–13 thus highlighting the accuracy of this noninvasive
technique. Micro-CT scan density analyses can also be used
to monitor the activity and browning of white fat pads,
which have been correlated to their densities.14–16
Our technique is novel in terms of in vivo tracking of both
biological and synthetic components of engineered tissue
over a long period of time. The 3D micro-CT scan method
showed a high accuracy and allowed to follow polymer
degradation in vivo, as well as fat volume changes, while
animals required only a mild anesthesia, and there was no
need for a contrast agent.
Table 2. Formulations of Oleic Acid-Loaded Poly(Lactic-Co-Glycolic Acid) Microspheres
Formulation
PLGA
concentration (w/v)
OA
concentration (w/v)
Mean volume
diameter (lm)
Span
value LE (%) EE (%)
1 4% 1.1% 39.1 1.4 25 94
2 4% 1.8% 45.3 1.3 48 110
3 4% 3.0% 57.0 1.4 79 109
4 4% 6.7% 177.3 3.4 90 55
EE, encapsulation efficiency; LE, loading efficiency.
FIG. 3. Micro-CT scan quantification of the densities of
the different tissues of interest in HU. Calculations were
normalized to muscle attenuation coefficients that were set
to 0. CT, computed tomography; HU, Hounsfield units.
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The degradation rate of PLGA depends on the copolymer
composition and microsphere size. PLGA is a drug release
system of choice, which is degraded by the hydrolysis of the
ester bonds into lactic and glycolic acids and, ultimately,
metabolized to carbon dioxide and water.17 The copolymer
PLGA has been already used for engineered constructs,
featuring human-rat adipocytes and an additional angio-
genic growth factor (basic fibroblast growth factor [bFGF])
on a 3D scaffold to induce neovascularization in vivo.18,19 In
another study, PLGA seeded with mesenchymal stem cells
FIG. 4. Micro-CT scan
images of the abdominal
mouse area of a naive mouse
(no biomaterial injected).
ROI are drawn sequentially
on in-depth 2D pictures on
one picture every 10, out of a
total of 512 coronal slices
(a). OsiriX software auto-
matically reconstructs the 3D
pictures and hence allows
precise volume quantification
(b). 2D, two-dimensional;
3D, three-dimensional; LIFP,
left inguinal fat pad; RIFP,
right inguinal fat pad; ROI,
regions of interest.
FIG. 5. Micro-CT scan image analysis of the abdominal mouse area of an empty microsphere-injected mouse before
injection at day 0 (a), after 15 days of injection (b). Before injection, only fat tissue is evidenced in the inguinal area in green
(c). At day 15, a clear contrast difference of the fat (green) and the injected material (blue) allows a precise delineation of the
ROI (d). Three-dimensional reconstruction of the control side noninjected (RIFP) and the injected site (LIFP) (e).
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was injected and newly formed tissue was assessed only once
postmortem.20 Recently, a group injected dibenzazepine-
loaded PLGA microspheres in the same target tissue to assess
fat browning in situ. They did not follow the polymer in vivo
and rather used fluorescent microscopy after the sacrifice.21
In our formulation, we designed microspheres that have
to be degraded over 3 months, which would allow a sus-
tained in vivo OA delivery of up to 3 months. Therefore, a
50:50 lactic to glycolide ratio was used to produce micro-
spheres with a homogenous size of 30–50 mm. According to
the literature, this copolymer ratio and size are known to
offer microspheres that are degraded over 2–3 months.22,23
In our study, the 3D micro-CT scan allowed to confirm that
these microspheres are resorbed over 90 days. By contrast,
high cross-linked HA, which is known to be degraded over a
longer time, was not resorbed completely at 90 days. The
CT images allow an accurate distinction of the various body
compartments at the tissue/organ level, including adipose
tissue. As quantitative measurements present a high accu-
racy and reproducibility, a CT scan is now recognized as the
gold standard in medical imaging.24,25
The aim of this study was to assess quantitatively the ef-
ficacy of the micro-CT scan technique to track PLGA poly-
mer in vivo and to follow its resorption, as well as to be able
to procure further evidence of fat pad volume enhancement.
The main advantage of this technology is the in vivo tracking
of both the injected polymer and the fat target tissue. It offers
the possibility to follow the same animal over a long period
of time. In addition, this long-term noninvasive monitoring
required the enrollment of fewer animals in the in vivo pro-
tocol because it was not necessary to sacrifice animals to
obtain measurements. The sensitivity of the technique was
proved by the observation of subtle fat pad changes (smallest
difference observed, 0.98mm3), including the smallest vol-
ume of synthetic volumes (1.26mm3) detected and followed
for resorption. Nevertheless, the main disadvantage of this
technique is the difficulty to assess in vivo the quality of fat
(i.e., apoptosis, angiogenesis), which requires histological
analysis.
To stick to the clinical protocol for Sculptra use, the con-
centration of PLA was low. This low polymer concentration
of PLA in Sculptra (e.g., 20 times less than microsphere or
OA-loaded microsphere formulations) could not be detected
by 3D CT scan and it is probable that this volume of synthetic
material (<0.5mm3) is the inferior limit of detection by this
technique. However, the highly cross-linked HA (Juvederm)
could easily be tracked in vivo over time. We observed a
stable volume up to 30 days with resorption starting from that
time point. The behavior of this product corresponds to our
clinical experiment and the company documentation, that is,
resorption of the product after 4–6 months.
Conclusion
Our in vivo model of fat pad injection was coupled with a
long-term in vivo tracking of the biomaterial using a micro-
CT scan approach. Automatic 3D reconstruction allowed a
precise assessment of the fat and biopolymer volumes. We
consider that this methodology represents a good platform to
track in vivo biodegradable products and to assess the effi-
cacy of adipose tissue engineering products for a bench-to-
bed approach.
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FIG. 7. Injected fat pad quantification in the different
experimental conditions along time. n= 12 animals per
group. Error bars = SEM. One-way ANOVA followed by
Dunnett’s multiple comparison test against saline experi-
mental condition. *p< 0.05, **p< 0.01, ***p < 0.001, and
****p£ 0.0001. ANOVA, analysis of variance.
FIG. 8. Product resorption results. n= 12 animals per group.
Error bars=SEM. One-way ANOVA followed by Dunnett’s
multiple comparison test. In each experimental group, com-
parison on the different time points against day 15. *p< 0.05,
**p< 0.01, ***p< 0.001, and ****p£ 0.0001.
FIG. 6. Noninjected fat pad quantification in the different
experimental conditions along time. n= 12 animals per
group. Error bars = SEM. SEM, standard error of the mean.
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